Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Geminivirus replication: rolling circle mechanism in plants].

Virologie (Montrouge, France)·2022

Same author

[Nanoviruses, small plant viruses: similarities and differences with geminiviruses].

Virologie (Montrouge, France)·2021

Same author

Probabilistic tsunami forecasting for early warning.

Nature communications·2021

Same author

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

European journal of neurology·2019

Same author

The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation.

Journal of thrombosis and haemostasis : JTH·2018

Same author

Hemostasis biomarkers in multiple sclerosis.

European journal of neurology·2018

Search research articles

Related Experiment Video

Updated: May 30, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

RNA-based therapeutic approaches for coagulation factor deficiencies.

M Pinotti¹, F Bernardi, A Dal Mas

¹Department of Biochemistry and Molecular Biology, University of Ferrara, Trieste, Italy.

Journal of Thrombosis and Haemostasis : JTH

|August 23, 2011

Summary

RNA-based therapies offer new hope for coagulation factor deficiencies by correcting gene expression. These approaches, including U1 snRNA modification, spliceosome-mediated RNA trans-splicing, and aminoglycoside drugs, show promise for treating genetic bleeding disorders.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: May 30, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Biochemistry
Molecular Biology
Genetics

Background:

Substitutive therapy improves quality of life for patients with coagulation factor deficiencies but has limitations.
Research is exploring alternative therapeutic strategies to overcome current treatment limitations.

Purpose of the Study:

To investigate RNA-based strategies for rescuing coagulation factor biosynthesis by targeting RNA processing and translation.
To restore altered gene expression while maintaining physiological tissue regulation.

Main Methods:

Modification of U1 small nuclear RNA (snRNA) to correct splicing in the F7 gene.
Spliceosome-mediated RNA trans-splicing (SMaRT) to produce normal FVIII mRNA.
Aminoglycoside drugs to induce ribosome readthrough of premature translation termination in FVII, FVIII, and FIX genes.

Main Results:

U1 snRNA modification led to correct mRNA synthesis and functional Factor VII secretion.
SMaRT produced normal FVIII mRNA and functional protein secretion.
Aminoglycosides induced ribosome readthrough, rescuing expression from very low to moderate levels.
Rescued expression levels, though ranging from low to moderate, could ameliorate disease phenotypes.

Conclusions:

RNA-based strategies demonstrate potential for treating coagulation factor deficiencies.
Further studies are needed to confirm the clinical translatability of these RNA-based approaches.
These findings open new therapeutic avenues for genetic bleeding disorders.